mRNA-1195

Phase 2RNA therapy

Moderna

mRNA-1195 is one of 41 biologic programs targeting Epstein-Barr virus infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epstein-Barr Virus InfectionActive, not recruiting

Multiple SclerosisRecruiting

Epstein-Barr Virus InfectionPhase 1

Active, not recruiting

Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

138 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 2

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 3

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 4

Vumerity

Biogen

Phase 3

5 5

Mayzent

Novartis

Phase 3

2 6

Activated Charcoal

Sanofi

Phase 3

1 7

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

2 8

Frexalimab

Sanofi

Phase 3

2 9

Tolebrutinib

Sanofi

Phase 3

5 10

PBR06

UUniversity Hospital, Bordeaux

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Multiple Sclerosis

NCT06735248

Clinical

Trials by Indication[1]

Multiple Sclerosis1 trial

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Recruiting· Moderna logo

Moderna·Phase 2·NCT06735248·180 enrolled

Epstein-Barr virus infection1 trial

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Participants 18 Through 55 Years of Age

Completed· Moderna logo

Moderna·Phase 1·NCT05831111·482 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for mRNA-1195. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1195 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1195. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Moderna

mRNA-1195

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Multiple Sclerosis1 trial

Epstein-Barr virus infection1 trial

References

Drug Info

Quick Facts

Related News